ABMT (Advanced BioMedical Technologies) Return-on-Tangible-Equity: 0.00% (As of Jul. 2021)


What is Advanced BioMedical Technologies Return-on-Tangible-Equity?

Advanced BioMedical Technologies ABMT Return-on-Tangible-Equity is 0.00% as of Jul. 2021.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Advanced BioMedical Technologies's annualized net income for the quarter that ended in Jul. 2021 was $-0.80 Mil. Advanced BioMedical Technologies's average shareholder tangible equity for the quarter that ended in Jul. 2021 was $-8.08 Mil. Therefore, Advanced BioMedical Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Jul. 2021 was N/A%.

The historical rank and industry rank for Advanced BioMedical Technologies's Return-on-Tangible-Equity or its related term are showing as below:

ABMT's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.08
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Advanced BioMedical Technologies  (OTCPK:ABMT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Advanced BioMedical Technologies Return-on-Tangible-Equity Related Terms


Advanced BioMedical Technologies Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Advanced BioMedical Technologies's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies Return-on-Tangible-Equity Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ABMT vs VYCO, ADMT, THMO: Return-on-Tangible-Equity Comparison

For the Medical Devices subindustry, Advanced BioMedical Technologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced BioMedical Technologies Return-on-Tangible-Equity vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's Return-on-Tangible-Equity falls into.



Advanced BioMedical Technologies Return-on-Tangible-Equity Calculation

Advanced BioMedical Technologies's annualized Return-on-Tangible-Equity for the fiscal year that ended in Oct. 2020 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Oct. 2020 )  (A: Oct. 2019 )(A: Oct. 2020 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Oct. 2020 )  (A: Oct. 2019 )(A: Oct. 2020 )
=-0.672/( (-6.478+-7.402 )/ 2 )
=-0.672/-6.94
=N/A %

Advanced BioMedical Technologies's annualized Return-on-Tangible-Equity for the quarter that ended in Jul. 2021 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Jul. 2021 )  (Q: Apr. 2021 )(Q: Jul. 2021 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Jul. 2021 )  (Q: Apr. 2021 )(Q: Jul. 2021 )
=-0.796/( (-7.969+-8.182)/ 2 )
=-0.796/-8.0755
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jul. 2021) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Advanced BioMedical Technologies (ABMT) has a Return-on-Tangible-Equity of 0.00% as of Jul. 2021. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Advanced BioMedical Technologies and its competitors.
Is Advanced BioMedical Technologies' Return-on-Tangible-Equity too high?
Advanced BioMedical Technologies' current Return-on-Tangible-Equity is 0.00%.
How does Advanced BioMedical Technologies' Return-on-Tangible-Equity compare to VYCO and ADMT?
Advanced BioMedical Technologies' Return-on-Tangible-Equity of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Advanced BioMedical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced BioMedical Technologies's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current Return-on-Tangible-Equity of 0.00%. The current Return-on-Tangible-Equity is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current Return-on-Tangible-Equity is 0.00% as of Jul. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced BioMedical Technologies Business Description

Address 535 Fifth Avenue, 4th Floor, New York, NY, USA, 10017
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.